Graham Capital Management adds Exelixis (EXEL) to its portfolio

Exelixis (EXEL) : Graham Capital Management added new position in Exelixis during the most recent quarter end. The investment management firm now holds 800,980 shares of Exelixis which is valued at $13,424,425 , the company said in a statement filed on Nov 14, 2016 with the SEC.Exelixis makes up approximately 2.35% of Graham Capital Management’s portfolio.

Other Hedge Funds, Including , Two Sigma Advisers Lp boosted its stake in EXEL in the latest quarter, The investment management firm added 817,313 additional shares and now holds a total of 1,796,103 shares of Exelixis which is valued at $30,102,686. Exelixis makes up approx 0.13% of Two Sigma Advisers Lp’s portfolio.Teacher Retirement System Of Texas reduced its stake in EXEL by selling 6,960 shares or 22.13% in the most recent quarter. The Hedge Fund company now holds 24,492 shares of EXEL which is valued at $291,700. Cibc World Markets added EXEL to its portfolio by purchasing 118,934 company shares during the most recent quarter which is valued at $1,213,127. Exelixis makes up approx 0.01% of Cibc World Markets’s portfolio.American Century Companies Inc reduced its stake in EXEL by selling 189,323 shares or 51.6% in the most recent quarter. The Hedge Fund company now holds 177,599 shares of EXEL which is valued at $1,919,845.

Exelixis opened for trading at $16.75 and hit $16.975 on the upside on Monday, eventually ending the session at $16.96, with a gain of 1.25% or 0.21 points. The heightened volatility saw the trading volume jump to 65,66,312 shares. Company has a market cap of $4,858 M.

On the company’s financial health, Exelixis reported $-0.04 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Nov 3, 2016. Analyst had a consensus of $-0.13. The company had revenue of $62.19 million for the quarter, compared to analysts expectations of $45.48 million. The company’s revenue was up 531.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.22 EPS.

Many Wall Street Analysts have commented on Exelixis. Deutsche Bank Initiated Exelixis on Nov 3, 2016 to “Buy”, Price Target of the shares are set at $17.Exelixis was Upgraded by Piper Jaffray to ” Overweight” on Oct 10, 2016. Company shares were Reiterated by Stifel on Sep 15, 2016 to “Buy”, Firm has raised the Price Target to $ 15 from a previous price target of $12 .

Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive metastatic medullary thyroid cancer (MTC) in the United States. The Company’s other programs include metastatic renal cell carcinoma (mRCC) a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888 a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).

Leave a Reply

Exelixis - Is it time to Sell?

Top Brokerage Firms are advising their investors on Exelixis. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.